| 2005 | Duodenal Somatostatinoma Associated with Diabetic Ketoacidosis Presumably Caused by Somatostatin-28 Hypersecretion | JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM |
| 2013 | Duodenum-preserving pancreatic head resection in benign and low-grade malignant pancreatic tumors
| Korean Journal of Hepato-Biliary-Pancreatic Surgery |
| 2017 | Durability of the virological response after lamivudine discontinuation in lamivudine-resistant patients with a complete virological response after lamivudine and adefovir combination therapy | JOURNAL OF MEDICAL VIROLOGY |
| 2021 | Duration of culturable SARS-CoV-2 within different specimens among mild and severe COVID-19 patients: A longitudinal study
| JOURNAL OF INFECTION |
| 2022 | Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y) | ANNALS OF ONCOLOGY |
| 2022 | Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis | ANNALS OF ONCOLOGY |
| 2022 | Durvalumab +/− Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase III POSEIDON Study | PNEUMOLOGIE |
| 2017 | Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2018 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study | LANCET ONCOLOGY |
| 2023 | Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2024 | Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial
| NATURE COMMUNICATIONS |
| 2023 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial | JAMA ONCOLOGY |
| 2018 | Dynamic change in left ventricular apical back rotation: a marker of diastolic suction with exercise | EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING |
| 2011 | Dynamic change of mitral apparatus as potential cause of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy.
| EUROPEAN JOURNAL OF ECHOCARDIOGRAPHY |
| 2021 | Dynamic changes in circulating PD-1(+)CD8(+)T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small-cell lung cancer | EUROPEAN JOURNAL OF CANCER |
| 2019 | Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy | LUNG CANCER |
| 2023 | Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma
| CANCER IMMUNOLOGY IMMUNOTHERAPY |
| 2018 | Dynamic Changes of CHA2DS2-VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study | THROMBOSIS AND HAEMOSTASIS |
| 2016 | Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Surrogate Biomarker for Bevacizumab in Colorectal Cancer Liver Metastasis: A Single-Arm, Exploratory Trial
| CANCER RESEARCH AND TREATMENT |
